|
1
|
Dawson MA and Kouzarides T: Cancer
epigenetics: From mechanism to therapy. Cell. 150:12–27. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bhatla T, Wang J, Morrison DJ, Raetz EA,
Burke MJ, Brown P and Carroll WL: Epigenetic reprogramming reverses
the relapse-specific gene expression signature and restores
chemosensitivity in childhood B-lymphoblastic leukemia. Blood.
119:5201–5210. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Baylin SB and Jones PA: A decade of
exploring the cancer epigenome-biological and translational
implications. Nat Rev Cancer. 11:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Roy DM, Walsh LA and Chan TA: Driver
mutations of cancer epigenomes. Protein Cell. 5:265–296. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sun Y, Chen BR and Deshpande A: Epigenetic
regulators in the development, maintenance, and therapeutic
targeting of acute myeloid leukemia. Front Oncol. 8:412018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Figueroa ME, Lugthart S, Li Y,
Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J,
van Putten W, Skrabanek L, et al: DNA methylation signatures
identify biologically distinct subtypes in acute myeloid leukemia.
Cancer Cell. 17:13–27. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jiang Y, Dunbar A, Gondek LP, Mohan S,
Rataul M, O'Keefe C, Sekeres M, Saunthararajah Y and Maciejewski
JP: Aberrant DNA methylation is a dominant mechanism in MDS
progression to AML. Blood. 113:1315–1325. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fey MF and Buske C; ESMO Guidelines
Working Group, : Acute myeloblastic leukaemias in adult patients:
ESMO clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 24 (Suppl 6):vi138–vi143. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fenaux P, Haase D, Santini V, Sanz GF,
Platzbecker U and Mey U; ESMO Guidelines Committee. Electronic
address: Clinicalguidelines@esmo.org: Myelodysplastic syndromes, :
ESMO clinical practice guidelines for diagnosis, treatment and
follow-up†☆. Ann Oncol. 32:142–156. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Seto E and Yoshida M: Erasers of histone
acetylation: The histone deacetylase enzymes. Cold Spring Harb
Perspect Biol. 6:a0187132014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tan P, Wei A, Mithraprabhu S, Cummings N,
Liu HB, Perugini M, Reed K, Avery S, Patil S, Walker P, et al: Dual
epigenetic targeting with panobinostat and azacitidine in acute
myeloid leukemia and high-risk myelodysplastic syndrome. Blood
Cancer J. 4:e1702014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Viré E, Brenner C, Deplus R, Blanchon L,
Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden
JM, et al: The polycomb group protein EZH2 directly controls DNA
methylation. Nature. 439:871–874. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gong K, Xie J, Yi H and Li W: CS055
(Chidamide/HBI-8000), a novel histone deacetylase inhibitor,
induces G1 arrest, ROS-dependent apoptosis and differentiation in
human leukaemia cells. Biochem J. 443:735–746. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu Y, Zhang P and Liu Y: Chidamide
tablets: HDAC inhibition to treat lymphoma. Drugs Today (Barc).
53:167–176. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu F, Guo H, Shi M, Liu S, Wei M, Sun K
and Chen Y: A combination of low-dose decitabine and chidamide
resulted in synergistic effects on the proliferation and apoptosis
of human myeloid leukemia cell lines. Am J Transl Res.
11:7644–7655. 2019.PubMed/NCBI
|
|
16
|
Jaatinen T and Laine J: Isolation of
mononuclear cells from human cord blood by ficoll-paque density
gradient. Curr Protoc Stem Cell Biol Chapte. Jun 1–2007.(Epub ahead
of print). doi: 10.1002/9780470151808.sc02a01s1.
|
|
17
|
Ambavaram MM and Pereira A: Setting up
reverse transcription quantitative-PCR experiments. Methods Mol
Biol. 678:45–54. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pollyea DA: Therapeutic advances in
first-line management of acute myeloid leukemia. J Natl Compr Canc
Netw. 17:1441–1443. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Döhner H, Estey EH, Amadori S, Appelbaum
FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson
RA, et al: Diagnosis and management of acute myeloid leukemia in
adults: Recommendations from an international expert panel, on
behalf of the European LeukemiaNet. Blood. 115:453–474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ganesan A, Nolan L, Crabb SJ and Packham
G: Epigenetic therapy: Histone acetylation, DNA methylation and
anti-cancer drug discovery. Curr Cancer Drug Targets. 9:963–981.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Anzai H, Frost P and Abbruzzese JL:
Synergistic cytotoxicity with 2′-deoxy-5-azacytidine and topotecan
in vitro and in vivo. Cancer Res. 52:2180–2185. 1992.PubMed/NCBI
|
|
22
|
Garcia-Manero G, Kantarjian HM,
Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M,
Wierda WG, Ravandi F, Koller C, et al: Phase 1/2 study of the
combination of 5-aza-2′-deoxycytidine with valproic acid in
patients with leukemia. Blood. 108:3271–3279. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Najem SA, Khawaja G, Hodroj MH, Babikian P
and Rizk S: Adjuvant epigenetic therapy of decitabine and
suberoylanilide hydroxamic acid exerts anti-neoplastic effects in
acute myeloid leukemia cells. Cells. 8:14802019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bewersdorf JP, Shallis R, Stahl M and
Zeidan AM: Epigenetic therapy combinations in acute myeloid
leukemia: What are the options? Ther Adv Hematol.
10:20406207188166982019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lübbert M and Kuendgen A: Combining DNA
methyltransferase and histone deacetylase inhibition to treat acute
myeloid leukemia/myelodysplastic syndrome: Achievements and
challenges. Cancer. 121:498–501. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu Z, Ding K, Li L, Liu H, Wang Y, Liu C
and Fu R: A novel histone deacetylase inhibitor Chidamide induces
G0/G1 arrest and apoptosis in myelodysplastic syndromes. Biomed
Pharmacother. 83:1032–1037. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sandor V, Senderowicz A, Mertins S,
Sackett D, Sausville E, Blagosklonny MV and Bates SE: P21-dependent
g(1)arrest with downregulation of cyclin D1 and upregulation of
cyclin E by the histone deacetylase inhibitor FR901228. Br J
Cancer. 83:817–825. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vijayaraghavalu S, Dermawan JK, Cheriyath
V and Labhasetwar V: Highly synergistic effect of sequential
treatment with epigenetic and anticancer drugs to overcome drug
resistance in breast cancer cells is mediated via activation of p21
gene expression leading to G2/M cycle arrest. Mol Pharm.
10:337–352. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hassan K, Bukhari KP, Zafar A, Malik MZ
and Akhtar MJ: Acute leukaemia in children-French-American-British
(FAB) classification and its relation to clinical features. J Pak
Med Assoc. 42:29–31. 1992.PubMed/NCBI
|
|
30
|
Heo SK, Noh EK, Yoon DJ, Jo JC, Koh S,
Baek JH, Park JH, Min YJ and Kim H: Rosmarinic acid potentiates
ATRA-induced macrophage differentiation in acute promyelocytic
leukemia NB4 cells. Eur J Pharmacol. 747:36–44. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sykes DB, Kfoury YS, Mercier FE, Wawer MJ,
Law JM, Haynes MK, Lewis TA, Schajnovitz A, Jain E, Lee D, et al:
Inhibition of dihydroorotate dehydrogenase overcomes
differentiation blockade in acute myeloid leukemia. Cell.
167:171–186 e15. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Re F, Arpinati M, Testoni N, Ricci P,
Terragna C, Preda P, Ruggeri D, Senese B, Chirumbolo G, Martelli V,
et al: Expression of CD86 in acute myelogenous leukemia is a marker
of dendritic/monocytic lineage. Exp Hematol. 30:126–134. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Krishna S, Low IC and Pervaiz S:
Regulation of mitochondrial metabolism: Yet another facet in the
biology of the oncoprotein Bcl-2. Biochem J. 435:545–551. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ebrahim AS, Sabbagh H, Liddane A, Raufi A,
Kandouz M and Al-Katib A: Hematologic malignancies: Newer
strategies to counter the BCL-2 protein. J Cancer Res Clin Oncol.
142:2013–2022. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang BR, Wan CL, Liu SB, Qiu QC, Wu TM,
Wang J, Li YY, Ge SS, Qiu Y, Shen XD, et al: A combined histone
deacetylases targeting strategy to overcome venetoclax plus
azacitidine regimen resistance in acute myeloid leukaemia: Three
case reports. Front Oncol. 11:7979412021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kaminskyy VO, Surova OV, Vaculova A and
Zhivotovsky B: Combined inhibition of DNA methyltransferase and
histone deacetylase restores caspase-8 expression and sensitizes
SCLC cells to TRAIL. Carcinogenesis. 32:1450–1458. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Al- Harbi S, Aljurf M, Mohty M, Almohareb
F and Ahmed SOA: An update on the molecular pathogenesis and
potential therapeutic targeting of AML with
t(8;21)(q22;q22.1);RUNX1-RUNX1T1. Blood Adv. 4:229–238. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ahmad K, Katryniok C, Scholz B, Merkens J,
Löscher D, Marschalek R and Steinhilber D: Inhibition of class I
HDACs abrogates the dominant effect of MLL-AF4 by activation of
wild-type MLL. Oncogenesis. 3:e1272014. View Article : Google Scholar : PubMed/NCBI
|
